community-acquired pneumonia
PSI (ATS/IDSA preferred) or CURB-65 guides site of care. Ward CAP: β-lactam + macrolide or respiratory fluoroquinolone (ATS/IDSA 2019 — the exam answer); β-lactam monotherapy is an evidence-based alternative for non-severe CAP without Legionella risk (CAP-START (2015)) and common Canadian stewardship practice. ICU: β-lactam + macrolide (or β-lactam + respiratory fluoroquinolone) — never fluoroquinolone monotherapy. Most penicillin-allergic patients can still receive ceftriaxone. 5 days standard; 3 days if stable at day 3 on the ward (PTC (2021)).
CAP empiric antibiotics — ward admission
- first-line (ATS/IDSA): ceftriaxone 1–2 g IV q24h + azithromycin 500 mg IV/PO q24h
- non-severe, no Legionella risk: ceftriaxone alone acceptable (CAP-START)
- always add azithromycin if CURB-65 ≥3, ICU/step-down, Legionella risk, or worsening
- if β-lactams must be avoided (SCAR, serum sickness, AIN, haemolysis): levofloxacin 750 mg IV/PO q24h — see penicillin allergy
- if prior respiratory MRSA: add vancomycin; stop if MRSA nasal swab and cultures negative
- if prior respiratory Pseudomonas: piperacillin-tazobactam 4.5 g IV q6h instead of ceftriaxone
- influenza season: influenza/COVID PCR → oseltamivir 75 mg PO BID if influenza positive
- PO step-down when clinically stable: cefuroxime 500 mg PO BID or amoxicillin-clavulanate 875/125 mg PO BID
- duration: 5 days (3 if stable at day 3; 7 if not yet stable at day 5)
Macrolide resistance in S. pneumoniae varies between Canadian centres — outpatient macrolide monotherapy only where resistance is <25%.
severity assessment
CURB-65
| criterion | points |
|---|---|
| Confusion (AMT ≤8 or new disorientation) | 1 |
| Urea >7 mmol/L | 1 |
| Respiratory rate ≥30/min | 1 |
| Blood pressure: SBP <90 or DBP ≤60 mmHg | 1 |
| age ≥65 | 1 |
| score | disposition |
|---|---|
| 0–1 | outpatient (mortality <3%) |
| 2 | short-stay / ward admission |
| 3–5 | ward or ICU (mortality 15–40%) |
ATS/IDSA 2019 prefers PSI (Pneumonia Severity Index) over CURB-65 for site-of-care decisions — PSI class I–II → outpatient; CRB-65 (no urea; ≥2 → consider admission) is the bedside/clinic shortcut.
Severe CAP (ATS/IDSA) — 1 major or ≥3 minor → ICU/step-down:
- major: invasive ventilation; septic shock needing vasopressors
- minor: RR ≥30; PaO₂/FiO₂ ≤250; multilobar infiltrates; confusion; urea ≥7 mmol/L; WBC <4 × 10⁹/L; platelets <100 × 10⁹/L; temperature <36 °C; hypotension needing aggressive fluids
CURB-65 underestimates severity in young patients — apply minor criteria alongside.
workup in admitted patients
- blood + sputum cultures: severe CAP, or prior MRSA/Pseudomonas — not routine in non-severe CAP
- Legionella urinary antigen: severe CAP or epidemiological risk (detects serogroup 1 only, ~70% of cases → negative result + fitting syndrome: keep macrolide cover)
- pneumococcal urinary antigen: severe CAP
- influenza/COVID PCR when circulating — treat influenza-positive inpatients with oseltamivir regardless of symptom duration
- MRSA nasal PCR: high negative predictive value → stop empiric vancomycin if negative
- procalcitonin: does not decide whether to start antibiotics in radiographic CAP; <0.25 µg/L favours viral but does not exclude bacterial CAP in the acutely ill
empiric therapy by setting
outpatient — no comorbidities
- amoxicillin 1 g PO TID × 5 days
- alternative: doxycycline 100 mg PO BID × 5 days
- azithromycin 500 mg day 1 → 250 mg days 2–5 only if local pneumococcal macrolide resistance <25%
outpatient — with comorbidities
Comorbidities = chronic heart, lung, liver, or renal disease; diabetes; alcohol use disorder; malignancy; asplenia.
- amoxicillin-clavulanate 875/125 mg PO BID (or cefuroxime 500 mg PO BID) + azithromycin or doxycycline
- or levofloxacin 750 mg PO daily (or moxifloxacin 400 mg PO daily)
inpatient — ward (non-severe)
- ATS/IDSA 2019: β-lactam (ceftriaxone, ampicillin-sulbactam) + macrolide, or respiratory fluoroquinolone monotherapy
- β-lactam monotherapy for non-severe CAP — CAP-START (2015): no difference in 90-day mortality vs β-lactam + macrolide; adopted by many Canadian stewardship programmes
- add azithromycin if Legionella risk: stagnant/aerosolised water exposure, institutional outbreak, June–October; suggestive features — confusion, diarrhoea, hyponatraemia, transaminitis, hypophosphataemia
- respiratory fluoroquinolone only when ceftriaxone cannot be used
inpatient — ICU
- ceftriaxone 2 g IV q24h + azithromycin 500 mg IV q24h, or ceftriaxone + levofloxacin 750 mg IV q24h
- never fluoroquinolone monotherapy
- Pseudomonas/MRSA cover only with prior respiratory isolation of that organism, or hospitalisation + IV antibiotics within 90 days (ATS/IDSA) — not for “HCAP” factors (dialysis, nursing home, structural lung disease) alone
- Pseudomonas: piperacillin-tazobactam 4.5 g IV q6h (or cefepime 2 g IV q8h) in place of ceftriaxone, still + azithromycin or levofloxacin for atypical cover
- MRSA: add vancomycin — de-escalate at 48 h if nasal PCR and cultures negative
suspected macroaspiration
- most is chemical pneumonitis → if rapid improvement, stop antibiotics and observe
- ceftriaxone covers oral anaerobes adequately — no added metronidazole or clindamycin (Bai, CHEST. 2024: extended anaerobic cover → no mortality benefit, more C. difficile)
- dedicated anaerobic cover only for lung abscess or empyema
penicillin allergy
- no shared side chain between penicillins and ceftriaxone → ceftriaxone can be given after most penicillin reactions, including hives and anaphylaxis (Sunnybrook excludes near-fatal reactions within 10 years)
- penicillin “allergy” that was GI upset or remote rash → standard β-lactam regimen, not a fluoroquinolone
- avoid all β-lactams only after SCAR (SJS/TEN, DRESS, AGEP), serum sickness, AIN, or haemolytic anaemia → levofloxacin 750 mg
- β-lactams contraindicated + ICU: levofloxacin + vancomycin if MRSA risk; aztreonam IV is Special Access Programme only in Canada
- de-labelling (PEN-FAST, direct oral challenge): see penicillin allergy
duration
| setting | duration |
|---|---|
| outpatient | 5 days |
| ward (non-severe) | 5 days; 3 days if stable at day 3 — PTC (2021): non-inferior to 8 days |
| not yet stable at day 5 | 7 days |
| ICU / severe | 7 days (PTC excluded ICU) |
| confirmed Legionella | ≥7 days |
| Mycoplasma/Chlamydophila | azithromycin 500 mg × 3 days sufficient |
| empyema / abscess | 2–6 weeks, guided by drainage and imaging |
Clinical stability (all required before stopping): T ≤37.8 °C, HR ≤100, RR ≤24, SBP ≥90, SpO₂ ≥90% on room air, normal mental status, tolerating PO. The same criteria trigger IV → PO switch.
adjunctive corticosteroids
- CAPE COD (2023): severe CAP in ICU (ventilated, or HFNO/NIV with FiO₂ ≥50% and PaO₂/FiO₂ <300, or PSI >130) → hydrocortisone 200 mg/day × 4 days, then taper for 8 days total if improving (14 days if not); 28-day mortality 6.2% vs 11.9% (NNT ~18)
- excluded septic shock and influenza — do not extrapolate to either
- ESCAPe (2022): methylprednisolone 40 mg/day — no significant mortality benefit
- SCCM 2024 focused update: suggests corticosteroids for severe CAP; not for non-severe CAP
- watch hyperglycaemia and superinfection
when to broaden
- no improvement by 48–72 h → repeat cultures, CT chest (abscess? empyema? alternative diagnosis?)
- parapneumonic effusion >1 cm → diagnostic thoracentesis (pH, glucose, LDH, Gram stain, culture)
- complicated parapneumonic effusion or empyema → chest tube + extended antibiotics
Prepared 2026-10-18. Not yet verified — check every number against the sources.